Want to join the conversation?
Douglas Tsao from Barclays Capital asks about Proair that if the company received a complete response letter or if there is a target action date from the FDA for the launch. $PRGO CEO John Hendrickson said the company did get some comments from the FDA and is working to address those comments and concerns.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.